Jostein Dahle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3088419/publications.pdf

Version: 2024-02-01

69 papers	1,434 citations	279798 23 h-index	377865 34 g-index
69 all docs	69 docs citations	69 times ranked	1371 citing authors

#	Article	IF	Citations
1	Targeted cancer therapy with a novel low-dose rate Î±-emitting radioimmunoconjugate. Blood, 2007, 110, 2049-2056.	1.4	80
2	Induction of delayed mutations and chromosomal instability in fibroblasts after UVA-, UVB-, and X-radiation. Cancer Research, 2003, 63, 1464-9.	0.9	79
3	Bystander effects in UV-induced genomic instability: antioxidants inhibit delayed mutagenesis induced by ultraviolet A and B radiation. Journal of Carcinogenesis, 2005, 4, 11.	2.5	65
4	The Mode of Cell Death Induced by Photodynamic Treatment Depends on Cell Density. Photochemistry and Photobiology, 1999, 70, 363-367.	2.5	58
5	Automated counting of mammalian cell colonies by means of a flat bed scanner and image processing. Cytometry, 2004, 60A, 182-188.	1.8	55
6	Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate Î±-particle radioimmunotherapy. Nuclear Medicine and Biology, 2006, 33, 271-279.	0.6	55
7	Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS ONE, 2012, 7, e42345.	2.5	51
8	Experimental Î±-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab. EJNMMI Research, 2011, 1, 18.	2.5	47
9	Preparation of TH²²⁷-Labeled Radioimmunoconjugates, Assessment of Serum Stability and Antigen Binding Ability. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 431-437.	1.0	45
10	Relative Biologic Effects of Low-Dose-Rate Î±-Emitting 227Th-Rituximab and Î²-Emitting 90Y-Tiuexetan-Ibritumomab Versus External Beam X-Radiation. International Journal of Radiation Oncology Biology Physics, 2008, 72, 186-192.	0.8	36
11	Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. Current Radiopharmaceuticals, 2013, 6, 20-27.	0.8	36
12	Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 93-102.	6.4	35
13	Treatment of HER2-Expressing Breast Cancer and Ovarian Cancer Cells With Alpha Particle-Emitting 227Th-Trastuzumab. International Journal of Radiation Oncology Biology Physics, 2011, 79, 563-570.	0.8	35
14	Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Research, 2013, 33, 85-95.	1.1	35
15	Pigmented Melanocytes Are Protected Against Ultraviolet-A-Induced Membrane Damage. Journal of Investigative Dermatology, 2003, 121, 564-569.	0.7	34
16	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances, 2020, 4, 4091-4101.	5.2	33
17	Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice. Current Radiopharmaceuticals, 2013, 6, 106-116.	0.8	32
18	Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0128816.	2.5	30

#	Article	IF	Citations
19	Bystander Effects in Cell Death Induced by Photodynamic Treatment, UVA Radiation and Inhibitors of ATP SynthesisÂ¶. Photochemistry and Photobiology, 2001, 73, 378.	2.5	29
20	Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate ¹⁷⁷Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2017, 58, 48-54.	5.0	29
21	Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. Nuclear Medicine Communications, 2012, 33, 838-847.	1.1	28
22	Gap Junctional Intercellular Communication is not a Major Mediator in the Bystander Effect in Photodynamic Treatment of MDCK II Cells. Radiation Research, 2000, 154, 331-341.	1.5	26
23	Bystander Effects may Modulate Ultraviolet A and B Radiation-Induced Delayed Mutagenesis. Radiation Research, 2005, 163, 289-295.	1.5	24
24	Overexpression of human OGG1 in mammalian cells decreases ultraviolet A induced mutagenesis. Cancer Letters, 2008, 267, 18-25.	7.2	22
25	The role of serotonin and p53 status in the radiation-induced bystander effect. International Journal of Radiation Biology, 2012, 88, 773-776.	1.8	22
26	Red Marrowâ€“Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with ¹⁷⁷Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibodyâ€“Radionuclide Conjugate. Journal of Nuclear Medicine, 2017, 58, 55-61.	5.0	22
27	Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkinâ€™s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS ONE, 2020, 15, e0230526.	2.5	22
28	177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice. PLoS ONE, 2014, 9, e103070.	2.5	22
29	Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1233-1241.	6.4	21
30	Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates. Current Radiopharmaceuticals, 2011, 4, 321-328.	0.8	21
31	In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227â€“DOTAâ€“Rituximab. International Journal of Radiation Oncology Biology Physics, 2009, 75, 886-895.	0.8	20
32	Melanin Synthesis may Sensitize Melanocytes to Oxidative DNA Damage by Ultraviolet A Radiation and Protect Melanocytes from Direct DNA Damage by Ultraviolet B Radiation. Pigment Cell & Melanoma Research, 2004, 17, 549-550.	3.6	19
33	Genome-Wide Microarray Analysis of Human Fibroblasts in Response to Î³ Radiation and the Radiation-Induced Bystander Effect. Radiation Research, 2011, 177, 35.	1.5	18
34	Combination of ¹⁷⁷Luâ€lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of nonâ€Hodgkin's lymphoma. European Journal of Haematology, 2018, 101, 522-531.	2.2	18
35	Evaluation of the Binding of Radiolabeled Rituximab to CD20-Positive Lymphoma Cells: AnIn VitroFeasibility Study Concerning Low-Dose-Rate Radioimmunotherapy with theÎ±-Emitter²²⁷Th. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 469-479.	1.0	17
36	Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibodyâ€“Radionuclide Conjugate¹⁷⁷Lu-Lilotomab Satetraxetan. Journal of Nuclear Medicine, 2018, 59, 704-710.	5.0	16

#	Article	IF	Citations
37	Targeted Alpha-Particle Therapy with 227Th-Labeled Antibodies. Current Radiopharmaceuticals, 2008, 1, 209-214.	0.8	16
38	Cooperative Inactivation of Cells in Microcolonies Treated with UVA Radiation. Radiation Research, 1999, 152, 174.	1.5	14
39	Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2311-2321.	6.4	14
40	The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines. Frontiers in Oncology, 2019, 9, 1301.	2.8	13
41	Comparing High LET ²²⁷Th- and Low LET ¹⁷⁷Lu-trastuzumab in Mice with HER-2 Positive SKBR-3 Xenografts. Current Radiopharmaceuticals, 2013, 6, 78-86.	0.8	13
42	A 238Pu irradiator for exposure of cultured cells with alpha-radiation: Construction, calibration and dosimetry. Applied Radiation and Isotopes, 2009, 67, 1998-2002.	1.5	12
43	The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia, 2020, 34, 1315-1328.	7.2	12
44	Transcriptional responses in irradiated and bystander fibroblasts after low dose Î±-particle radiation. International Journal of Radiation Biology, 2012, 88, 713-719.	1.8	11
45	A laboratory inter-comparison of the importance of serum serotonin levels in the measurement of a range of radiation-induced bystander effects: Overview of study and results presentation. International Journal of Radiation Biology, 2012, 88, 763-769.	1.8	9
46	Modifications in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters After Î±-Particle-Emitting 227Th-trastuzumab Therapy of HER2-Expressing Ovarian Cancer Xenografts. International Journal of Radiation Oncology Biology Physics, 2013, 87, 153-159.	0.8	9
47	¹⁷⁷Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. Journal of Nuclear Medicine, 2020, 61, 1468-1475.	5.0	9
48	Multiplex Polymerase Chain Reaction Analysis of UV-Aâ€“ and UV-Bâ€“induced Delayed and Early Mutations in V79 Chinese Hamster CellsÂ¶. Photochemistry and Photobiology, 2005, 81, 114.	2.5	9
49	Dosimetry of a 238Pu-based alpha-particle irradiator and its biological application in a study of the bystander effect. Anticancer Research, 2011, 31, 2113-20.	1.1	9
50	Increased level of oxidative stress in genomically unstable cell clones. Journal of Photochemistry and Photobiology B: Biology, 2004, 74, 23-28.	3.8	8
51	FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1902-1914.	6.4	6
52	Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors. Anticancer Research, 2014, 34, 3263-9.	1.1	6
53	The pheomelanin precursor 5-S-cysteinyldopa protects melanocytes from membrane damage induced by ultraviolet A radiation. Cancer Letters, 2005, 221, 131-134.	7.2	5
54	Myelosuppression in patients treated with¹⁷⁷Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable. Acta OncolÃ³gica, 2021, 60, 1481-1488.	1.8	5

#	Article	IF	Citations
55	A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. Blood, 2014, 124, 3094-3094.	1.4	3
56	Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). Blood, 2018, 132, 4422-4422.	1.4	3
57	89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma. Scientific Reports, 2022, 12, 6286.	3.3	3
58	FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphomaâ€"Are We Hitting the Target?. Molecular Imaging and Biology, 2022, 24, 807-817.	2.6	3
59	177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. Blood, 2016, 128, 1780-1780.	1.4	2
60	A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding. Nuclear Medicine Communications, 2007, 28, 742-747.	1.1	1
61	Bystander Effects in Cell Death Induced by Photodynamic Treatment, UVA Radiation and Inhibitors of ATP SynthesisÂ¶. Photochemistry and Photobiology, 2007, 73, 378-387.	2.5	1
62	Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkinâ€™s lymphoma in vitro. PLoS ONE, 2022, 17, e0267543.	2.5	1
63	<title>Cooperative effects of photosensitized cell killing</title>. , 1999, , .		0
64	Multiplex Polymerase Chain Reaction Analysis of UVâ€Aâ€“ and UVâ€Bâ€“induced Delayed and Early Mutations in V79 Chinese Hamster Cells^{Â¶}. Photochemistry and Photobiology, 2005, 81, 114-119.	2.5	0
65	Abstract LB-252: Efficacy and safety results of BetalutinÂ® (177Lu-DOTA-HH1) in a phase I/II study of patients with non-hodgkin B-cell lymphoma (NHL). , 2016, , .		0
66	Combination of 177lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma. Blood, 2016, 128, 4189-4189.	1.4	0
67	The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177lu-Satetraxetan-Lilotomab. Blood, 2016, 128, 5339-5339.	1.4	0
68	Abstract 848: In vitro and in vivo evaluation of the beta-emitting lutetium-177 labeled anti-CD37 antibody radionuclide conjugate177Lu-NNV003 in DLBCL, CLL and MCL models. , 2018, , .		0
69	Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines. Blood, 2018, 132, 1371-1371.	1.4	0